NLSP Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 12:51):

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders...

Stats
Today's Volume	13 479.00
Average Volume	571 138
Market Cap	5.53M
EPS	$0 ( 2023-08-04 )
Next earnings date	( $0 ) 2024-05-03
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.280
ATR14	$0.00300 (2.14%)

Volume Correlation

Long: -0.07 (neutral)

Short: 0.58 (weak)

Signal:(50.619) Neutral

NLS Pharmaceutics AG Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

NLS Pharmaceutics AG Correlation - Currency/Commodity

0.28
( neutral )

0.19
( neutral )

0.00
( neutral )

0.13
( neutral )

NLS Pharmaceutics AG Financials

Annual	2022
Revenue:	$0
Gross Profit:	$-11 408.00 (0.00 %)
EPS:	$-0.840

Q2	2023
Revenue:	$0
Gross Profit:	$-5 704.00 (0.00 %)
EPS:	$-0.200

Q4	2022
Revenue:	$0
Gross Profit:	$-5 704.00 (0.00 %)
EPS:	$-0.290

Q2	2022
Revenue:	$0
Gross Profit:	$-5 704.00 (0.00 %)
EPS:	$-0.540

Financial Reports:

No articles found.

NLS Pharmaceutics AG

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.